miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

András Lánczky, Ádám Nagy, Giulia Bottai, Gyöngyi Munkácsy, András Szabó, Libero Santarpia, B. Györffy

Research output: Contribution to journalArticle

263 Citations (Scopus)

Abstract

Purpose: The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, we developed an integrated online bioinformatic tool to validate the prognostic relevance of miRNAs in breast cancer. Methods: A database was set up by searching the GEO, EGA, TCGA, and PubMed repositories to identify datasets with published miRNA expression and clinical data. Kaplan–Meier survival analysis was performed to validate the prognostic value of a set of 41 previously published survival-associated miRNAs. Results: All together 2178 samples from four independent datasets were integrated into the system including the expression of 1052 distinct human miRNAs. In addition, the web-tool allows for the selection of patients, which can be filtered by receptors status, lymph node involvement, histological grade, and treatments. The complete analysis tool can be accessed online at: www.kmplot.com/mirpower. We used this tool to analyze a large number of deregulated miRNAs associated with breast cancer features and outcome, and confirmed the prognostic value of 26 miRNAs. A significant correlation in three out of four datasets was validated only for miR-29c and miR-101. Conclusions: In summary, we established an integrated platform capable to mine all available miRNA data to perform a survival analysis for the identification and validation of prognostic miRNA markers in breast cancer.

Original languageEnglish
Pages (from-to)439-446
Number of pages8
JournalBreast Cancer Research and Treatment
Volume160
Issue number3
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

MicroRNAs
Breast Neoplasms
Survival
Survival Analysis
Tumor Biomarkers
Computational Biology
PubMed
Patient Selection
Biomarkers
Lymph Nodes
Databases
Research

Keywords

  • Biomarkers
  • Breast cancer
  • Gene expression
  • MicroRNAs
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

miRpower : a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. / Lánczky, András; Nagy, Ádám; Bottai, Giulia; Munkácsy, Gyöngyi; Szabó, András; Santarpia, Libero; Györffy, B.

In: Breast Cancer Research and Treatment, Vol. 160, No. 3, 01.12.2016, p. 439-446.

Research output: Contribution to journalArticle

Lánczky, András ; Nagy, Ádám ; Bottai, Giulia ; Munkácsy, Gyöngyi ; Szabó, András ; Santarpia, Libero ; Györffy, B. / miRpower : a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. In: Breast Cancer Research and Treatment. 2016 ; Vol. 160, No. 3. pp. 439-446.
@article{4fc504a9a5d5450ab1d53c59cf61048a,
title = "miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients",
abstract = "Purpose: The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, we developed an integrated online bioinformatic tool to validate the prognostic relevance of miRNAs in breast cancer. Methods: A database was set up by searching the GEO, EGA, TCGA, and PubMed repositories to identify datasets with published miRNA expression and clinical data. Kaplan–Meier survival analysis was performed to validate the prognostic value of a set of 41 previously published survival-associated miRNAs. Results: All together 2178 samples from four independent datasets were integrated into the system including the expression of 1052 distinct human miRNAs. In addition, the web-tool allows for the selection of patients, which can be filtered by receptors status, lymph node involvement, histological grade, and treatments. The complete analysis tool can be accessed online at: www.kmplot.com/mirpower. We used this tool to analyze a large number of deregulated miRNAs associated with breast cancer features and outcome, and confirmed the prognostic value of 26 miRNAs. A significant correlation in three out of four datasets was validated only for miR-29c and miR-101. Conclusions: In summary, we established an integrated platform capable to mine all available miRNA data to perform a survival analysis for the identification and validation of prognostic miRNA markers in breast cancer.",
keywords = "Biomarkers, Breast cancer, Gene expression, MicroRNAs, Prognosis, Survival",
author = "Andr{\'a}s L{\'a}nczky and {\'A}d{\'a}m Nagy and Giulia Bottai and Gy{\"o}ngyi Munk{\'a}csy and Andr{\'a}s Szab{\'o} and Libero Santarpia and B. Gy{\"o}rffy",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s10549-016-4013-7",
language = "English",
volume = "160",
pages = "439--446",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - miRpower

T2 - a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

AU - Lánczky, András

AU - Nagy, Ádám

AU - Bottai, Giulia

AU - Munkácsy, Gyöngyi

AU - Szabó, András

AU - Santarpia, Libero

AU - Györffy, B.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Purpose: The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, we developed an integrated online bioinformatic tool to validate the prognostic relevance of miRNAs in breast cancer. Methods: A database was set up by searching the GEO, EGA, TCGA, and PubMed repositories to identify datasets with published miRNA expression and clinical data. Kaplan–Meier survival analysis was performed to validate the prognostic value of a set of 41 previously published survival-associated miRNAs. Results: All together 2178 samples from four independent datasets were integrated into the system including the expression of 1052 distinct human miRNAs. In addition, the web-tool allows for the selection of patients, which can be filtered by receptors status, lymph node involvement, histological grade, and treatments. The complete analysis tool can be accessed online at: www.kmplot.com/mirpower. We used this tool to analyze a large number of deregulated miRNAs associated with breast cancer features and outcome, and confirmed the prognostic value of 26 miRNAs. A significant correlation in three out of four datasets was validated only for miR-29c and miR-101. Conclusions: In summary, we established an integrated platform capable to mine all available miRNA data to perform a survival analysis for the identification and validation of prognostic miRNA markers in breast cancer.

AB - Purpose: The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, we developed an integrated online bioinformatic tool to validate the prognostic relevance of miRNAs in breast cancer. Methods: A database was set up by searching the GEO, EGA, TCGA, and PubMed repositories to identify datasets with published miRNA expression and clinical data. Kaplan–Meier survival analysis was performed to validate the prognostic value of a set of 41 previously published survival-associated miRNAs. Results: All together 2178 samples from four independent datasets were integrated into the system including the expression of 1052 distinct human miRNAs. In addition, the web-tool allows for the selection of patients, which can be filtered by receptors status, lymph node involvement, histological grade, and treatments. The complete analysis tool can be accessed online at: www.kmplot.com/mirpower. We used this tool to analyze a large number of deregulated miRNAs associated with breast cancer features and outcome, and confirmed the prognostic value of 26 miRNAs. A significant correlation in three out of four datasets was validated only for miR-29c and miR-101. Conclusions: In summary, we established an integrated platform capable to mine all available miRNA data to perform a survival analysis for the identification and validation of prognostic miRNA markers in breast cancer.

KW - Biomarkers

KW - Breast cancer

KW - Gene expression

KW - MicroRNAs

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84991320279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991320279&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-4013-7

DO - 10.1007/s10549-016-4013-7

M3 - Article

C2 - 27744485

AN - SCOPUS:84991320279

VL - 160

SP - 439

EP - 446

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -